Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10702438			
Filing Date		2003-11-07			
First Named Inventor DE C		CARVALHO, Raquel			
Art Unit		1616			
Examiner Name	Shan	mudi S. Gollamudi			
Attorney Docket Number		05725.1258-00000			

	U.S.PATENTS							Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹				Releva	Columns,Lines whe ant Passages or Rel s Appear		
	1									
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	aminer Cite Publication Number Kind Code ¹ Publication Name of Patentee or Applican of cited Document			Releva	Columns,Lines who ant Passages or Rel s Appear					
	1									
If you wisi	h to a	dd additional U.S. Publi	shed Ap	p		n information p		d button	Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	74
	1	JP-T-H08-505394	JP				Eastman Kodak C	0.		
	2	WO 94/15575	us			1994-07-21	Eastman Kodak C	D.		
	3	JP-A-2000-204025	JP			2000-07-25	Kose Corp.			

INFORMATION DISCLOSURE First Named Inventor DE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

JP

4

JP-A-2000-026254

Application Number		10702438		
Filing Date		2003-11-07		
First Named Inventor	DE CARVALHO, Raquel			
Art Unit		1616		
Examiner Name	Shan	mudi S. Gollamudi		
Attornov Docket Number		05725 1250 00000		

Date Considered

Kao Corp.

	5	JP-A-H09-255534	JP		1997-09-30	Shiseido Co. Ltd.					
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										
	1 English language abstract of JP-A-2000-264025, July 25, 2000.										
	2 English language abstract of JP-A-2000-026254, January 25, 2000.										
	3 English language abstract of JP-A-H09-255534, September 30, 1997.										

2000-01-25

See Not Codes of USPTO Peter Documents at wave USPTO.QCV or MPEP 901.04. 2 Fater date that secure the document, by the Nov-Netro rode (NIPC) Securidad ST 3). Yes Uspanses patered occurrent, by the Nov-Netro rode (NIPC) Securidad ST 3). Yes Uspanses patered occurrent, by the Nov-Netro rode (NIPC) Securidad ST 40 Empress mad precedule in secular to the original personal representation of the NIPC Securidad ST 46 possible. "Application is not here if Employee interesting the representation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10702438		
Filing Date		2003-11-07		
First Named Inventor	DE CARVALHO, Raquel			
Art Unit		1616		
Examiner Name	Sharmudi S. Gollamudi			
Attorney Docket Number		05725.1258-00000		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

ΩR

That no item of Information contained in the information disclosure statement was cited in a communication from a foreign peter office in a counterpart foreign application, and to the knowledge of the person signifing the certification after making reasonable inquiry, no tern of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,579(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Hilary Dorr Lang/	Date (YYYY-MM-DD)	2006-05-22
Name/Print	Hitary Dorr Lang	Registration Number	51917

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.